- $5.00bn
- $5.14bn
- $953.68m
- 99
- 20
- 80
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 29.68 | ||
| PEG Ratio (f) | 1.76 | ||
| EPS Growth (f) | 20.35% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.14 | ||
| Price to Tang. Book | 20.02 | ||
| Price to Free Cashflow | 33.15 | ||
| Price to Sales | 5.18 | ||
| EV to EBITDA | 21.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.01% | ||
| Return on Equity | 11.94% | ||
| Operating Margin | 19.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 703.64 | 799.02 | 942.36 | 922.44 | 953.68 | 1,008.93 | 1,080.57 | 8.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +5.84 | +10.75 | +11.75 | -0.95 | +20.2 | +27.75 | +7.92 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
Directors
- Theodore Harris CHM (56)
- Martin Bengtsson CFO (42)
- James Hyde SVP
- William Backus CAO (54)
- Mark Stach GCN (58)
- John Televantos LED (68)
- Kathleen Fish DRC
- David Fischer IND (58)
- Daniel Knutson IND (64)
- Joyce Lee IND (48)
- Perry Premdas IND (68)
- Matthew Wineinger IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 30th, 1967
- Public Since
- June 3rd, 1986
- No. of Shareholders
- 59
- No. of Employees
- 1,379
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 32,617,301
- Address
- 5 Paragon Drive, MONTVALE, 07645
- Web
- https://balchem.com/
- Phone
- +1 8453265600
- Auditors
- RSM US LLP
Upcoming Events for BCPC
Balchem Corp Annual Shareholders Meeting
Q2 2025 Balchem Corp Earnings Release
Q3 2025 Balchem Corp Earnings Release
Similar to BCPC
Bioceres Crop Solutions
NASDAQ Global Select Market
Gulf Resources
NASDAQ Global Select Market
Hawkins
NASDAQ Global Select Market
Innospec
NASDAQ Global Select Market
Linde
NASDAQ Global Select Market
FAQ
What is the Balchem share price?
As of Today at 19:29 UTC, shares in Balchem are trading at $153.64. This share price information is delayed by 15 minutes.
How has the Balchem share price performed this year?
Shares in Balchem last closed at $153.64 and the price had moved by +10.93% over the past 365 days. In terms of relative price strength the Balchem share price has outperformed the S&P500 Index by +2.39% over the past year.
What are the analyst and broker recommendations for Balchem?
The overall consensus recommendation for Balchem is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Balchem dividend yield?
The Balchem dividend yield is 0.57% based on the trailing twelve month period.
Does Balchem pay a dividend?
Last year, Balchem paid a total dividend of $0.87, and it currently has a trailing dividend yield of 0.57%. We do not have any data on when Balchem is to next pay dividends.
When does Balchem next pay dividends?
We do not have data on when Balchem is to next pay dividends. The historic dividend yield on Balchem shares is currently 0.57%.
How do I buy Balchem shares?
To buy shares in Balchem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Balchem?
As of the previous close price of $153.64, shares in Balchem had a market capitalisation of $5.00bn.
Where are Balchem shares listed?
Here are the trading details for Balchem:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BCPC
What kind of share is Balchem?
Based on an overall assessment of its quality, value and momentum Balchem is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Balchem share price forecast for 2025?
The analyst consensus target price for shares in Balchem is $199.33. That is 29.74% above the last closing price of $153.64.
Analysts covering Balchem currently have a consensus Earnings Per Share (EPS) forecast of $5.05 for the next financial year.
Find out moreWhat is the trend in the Balchem share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Balchem. Over the past six months, its share price has underperformed the S&P500 Index by -5.56%.
As of the last closing price of $153.64, shares in Balchem were trading -8.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Balchem PE Ratio?
The Balchem PE ratio based on its reported earnings over the past 12 months is 29.68. The shares last closed at $153.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Balchem?
Balchem's management team is headed by:
- Theodore Harris - CHM
- Martin Bengtsson - CFO
- James Hyde - SVP
- William Backus - CAO
- Mark Stach - GCN
- John Televantos - LED
- Kathleen Fish - DRC
- David Fischer - IND
- Daniel Knutson - IND
- Joyce Lee - IND
- Perry Premdas - IND
- Matthew Wineinger - IND